Table 1.
Patient and tumor characteristics.
| N = 40 (%) | |
|---|---|
| Median age, years [range] | 60 [31–77] |
| Gender | |
| Male | 26 (65) |
| Female | 14 (35) |
| ECOG PS | |
| 0 | 21 (53) |
| 1 | 15 (38) |
| 2 | 3 (8) |
| Primary site | |
| Parotid gland | 22 (55) |
| Submandibular gland | 12 (30) |
| Minor salivary gland | 6 (15) |
| Histology | |
| Mucoepidermoid carcinoma | 2 (5) |
| Adenoid cystic carcinoma | 10 (25) |
| Acinic cell carcinoma | 1 (3) |
| Adenocarcinoma, NOS (ANOS) | 8 (20) |
| Salivary duct carcinoma (SDC) | 8 (20) |
| Carcinoma ex pleomorphic adenoma (CEPA) | 6 (15) |
| Poorly differentiated carcinoma | 4 (10) |
| Carcinoma, NOS | 1 (3) |
| Prior systemic therapy line† | |
| 0 | 29 (72.5) |
| 1 | 9 (22.5) |
| 2 | 2 (5) |
| Median baseline of creatinine clearance using the Cockcroft-Gault formula (mL/min) [range] | 85.9 [43.3–140.2] |
| Hormone receptor expression (overall) | |
| AR-positive and HER2-positive | 6 (15) |
| AR-positive and HER2-negative | 5 (13) |
| Both negative or uncertain | 29 (73) |
| Hormone receptor expression in representative subtypes | |
| ANOS (n=8) | |
| AR-positive | 4 (25) |
| HER2-positive | 2 (12.5) |
| SDC (n=8) | |
| AR-positive | 5 (62.5) |
| HER2-positive | 3 (37.5) |
| CEPA (n=6) | |
| AR-positive | 3 (50.0) |
| HER2-positive | 2 (33.3) |
| Prior hormone therapy | |
| Yes | 8 (20) |
| No | 32 (80) |
| Next-generation sequencing | |
| Yes | 15 (38) |
| No | 25 (62) |
†The number indicates the treatment line in which chemotherapy and hormone therapy were used as systemic therapy for R/M SGC. AR, androgen receptor; HER2, human epidermal growth factor receptor 2.